Radiographic marginal bone level · People with at least one dental implant affected by perimplantitis
1 finding from 1 review
Marginal bone level change · People with at least one dental implant affected by perimplantitis
Er:YAG laser showed no clear difference in radiographic marginal bone level change compared with air-abrasive device (Perio-Flow); GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
1 finding from 1 review
no estimate extracted
2 studies
GRADE not reported
Marginal bone level change · Patients with compromised teeth to be extracted who require single dental implants in fresh postextraction sockets
Immediate implants (placed in a fresh extraction socket just after… showed no clear difference in perimplant marginal bone level changes compared with delayed implants (placed at least 2 months after extraction, in…; GRADE not reported.
1 finding from 1 review
Component loosening / revisions ‐ not reported · Patients with rheumatoid shoulder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prosthesis/implant failure (1 year) · Patients with horizontally resorbed maxillary sites needing single implants
Autogenous bone block from the chin showed no clear difference in prosthesis/implant failure (1 year) compared with 100% Bio-Oss + resorbable barrier; GRADE not reported.
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
Buspirone showed no clear difference in benzodiazepine discontinuation, longest compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Time to occurrence of new ulcer · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing a new ulcer · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Horizontal bone augmentation (any technique) vs No augmentation
Outcome not reported · Patients with horizontally resorbed maxillary sites needing single implants
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in health‐related quality of life (HRQOL) ‐ not measured · patients with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · patients with hirsutism
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg showed no clear difference in proportion of participants who reported an adverse event compared with ethinyl estradiol 30 μg + desogestrel 0.15 mg (moderate certainty).
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · patients with hirsutism
1 finding from 1 review
Change in serum androgen levels · patients with hirsutism
1 finding from 1 review
Change in BMI · patients with hirsutism
1 finding from 1 review
Improvement of other clinical signs of hyperandrogenism Acne score ‐ grade 1 to 4 (higher is worse) · patients with hirsutism
1 finding from 1 review
Prosthesis/implant failure (1 year) · Patients with horizontally resorbed maxillary sites needing single implants
Autogenous bone block from the chin + resorbable barrier showed no clear difference in prosthesis/implant failure (1 year) compared with 100% Bio-Oss + resorbable barrier; GRADE not reported.
1 finding from 1 review
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review